ARWRHealthcare · BiotechnologyThe 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +21.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 6 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +21.2% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $101 → $123 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Buy | $100 → $115 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | $100 → $120 |
| 23 July 2026 | Piper Sandler | Reiterates | Overweight | $110 → $126 |
| 22 July 2026 | Chardan Capital | Maintains | Buy | $90 → $115 |
| 22 July 2026 | Chardan Capital | Maintains | Buy | — |
| 17 July 2026 | JP Morgan | Maintains | Overweight | $88 → $95 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | — |
| 14 July 2026 | Stifel | Initiates | Buy | $98 |
| 14 July 2026 | Stifel | Initiates | Buy | — |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2026 | Chardan Capital | Maintains | Buy | — |
| 17 June 2026 | Leerink Partners | Maintains | Market Perform | — |
| 13 May 2026 | Bernstein | Maintains | Market Perform | — |
| 8 May 2026 | RBC Capital | Maintains | Outperform | — |
| 1 May 2026 | JP Morgan | Initiates | Overweight | — |
| 21 Apr 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 25 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2026 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 9% of US stocks
Cheaper than 5% of US stocks
Cheaper than 94% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 11% of US stocks
Higher than 10% of US stocks
Higher than 23% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARWR appears on the weeks it earns a place.
Seeking Alpha published the transcript of Arrowhead Pharmaceuticals' Q3 2026 earnings call. The excerpt provides no additional details beyond the transcript's availability.
Why it matters — The earnings call transcript gives ARWR watchers a record of management's discussion of the company's quarterly results and outlook.
On its Q3 earnings call, Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia, accelerating plans for a supplemental New Drug Application. The company also highlighted continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome.
Why it matters — For Arrowhead watchers, the positive Phase III data advancing plozasiran and continued REDEMPLO launch growth point to progress in both its pipeline and its commercial rollout.
Arrowhead Pharmaceuticals announced its financial results for the fiscal 2026 third quarter ended June 30, 2026, and is hosting a conference call on August 4, 2026, to discuss them. President and CEO Christopher Anzalone cited recent transformational events supporting continued growth, including recently announced topline results.
Why it matters — ARWR watchers would care because the quarterly report and CEO commentary provide an update on the company's recent clinical developments and its outlook for continued growth.
Arrowhead Pharmaceuticals announced it has signed an agreement with an undisclosed third party to acquire an FDA Rare Pediatric Disease Priority Review Voucher. The company plans to use the voucher for its upcoming Supplemental New Drug Application submission for plozasiran, expected before the end of 2026, to seek approval to expand the approved indication.
Why it matters — The priority review voucher could expedite the FDA review of the planned plozasiran sNDA, a key upcoming regulatory milestone for Arrowhead.
Arrowhead Pharmaceuticals announced that, on July 16, 2026, its Board of Directors approved inducement grants under NASDAQ Listing Rule 5635(c)(4) to 95 new employees as an inducement to employment. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units and are made outside the company's stockholder-approved equity incentive plans.
Why it matters — ARWR watchers would care because the new equity awards to incoming employees signal ongoing hiring and potential dilution outside the company's shareholder-approved compensation plans.
The 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $95 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Arrowhead Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Aug 2026, Arrowhead Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +21.2% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 54 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $95 to $126 over the next 12 months.
Arrowhead Pharmaceuticals, Inc. returned +426.2% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production.
The most recent item we track (Seeking Alpha, 5 Aug 2026): "Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Arrowhead Pharmaceuticals' Q3 2026 earnings call. The excerpt provides no additional details beyond the transcript's availability.
Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production. The company uses proprietary RNA chemistries and its TRiM platform to selectively silence disease-causing genes across multiple tissues, including liver, lung, muscle, adipose, and central nervous system. Arrowhead’s portfolio spans cardiometabolic and cardiovascular disorders, liver diseases such as alpha-1 antitrypsin deficiency and hepatitis B, pulmonary conditions including idiopathic pulmonary fibrosis and mucus-obstructive lung disease, and rare genetic diseases affecting muscle and complement-mediated pathways. Its first approved product, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome as an adjunct to diet. Beyond wholly owned programs, Arrowhead also collaborates with large pharmaceutical partners to extend the reach of its RNAi therapeutics globally. Founded in 1989 and headquartered in Pasadena, California, with additional R&D and manufacturing facilities in Wisconsin, San Diego, and Ireland, Arrowhead today operates as a specialized player within the biotechnology and healthcare sectors.
CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com